Search
Memorial Sloan Kettering Cancer Center (MSK) announces the following awards and appointments.
The word “epigenetic” literally means “above the genes.” Calico cats demonstrate a type of epigenetic inheritance called X-inactivation.
Learn how MSK researchers led the way in the approval of a new mantle cell lymphoma CAR T cell treatment.
Memorial Sloan Kettering Cancer Center (MSK) today announced the establishment of The Starr Foundation Program for Discovery Science, a pioneering new initiative made possible by a generous $50 million gift from The Starr Foundation. The program will support the visionary work of scientists at the Sloan Kettering Institute (SKI), the research arm of MSK, by funding foundational laboratory research that will drive the next generation of cancer breakthroughs and ultimately improve the lives of people facing cancer around the world.
Memorial Sloan Kettering Cancer Center (MSKCC) has opened a new 72,000-square-foot surgical center that was uniquely designed to take advantage of the latest medical technology while enhancing patient safety and efficiency of care.
Synovial sarcoma is an aggressive cancer primarily affecting children and young adults. A new study gets to the bottom of it.
Postoperative survival after surgery for spinal metastases has improved over the past 20 years, particularly in patients with kidney, breast, lung, and colon tumors metastatic to the spine.
Memorial Sloan Kettering Cancer Center (MSK) and Miami Cancer Institute at Baptist Health South Florida announce the beginning of a dynamic and forward-thinking collaboration aimed at improving patient access to the latest and most effective cancer treatment advances and the highest caliber of cancer care. Leaders from both institutions have confirmed the first step in announcing their recently signed agreement for Miami Cancer Institute to join the Memorial Sloan Kettering Cancer Alliance.
An international study led by researchers at Memorial Sloan Kettering Cancer Center has identified genetic variants in women with BRCA2 mutations that may increase or decrease their risk of developing breast cancer.
GSK congratulates ten of its doctoral students who have been recognized by esteemed organizations for their promising academic research.